Financial Review: Shanghai Pharmaceuticals (SHPMF) & Its Rivals

Profitability

This table compares Shanghai Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Shanghai Pharmaceuticals	N/A	N/A	N/A
Shanghai Pharmaceuticals Competitors	-5.58%	-137.93%	-0.40%

Dividends

Shanghai Pharmaceuticals pays an annual dividend of $0.26 per share and has a dividend yield of 18.7%. Shanghai Pharmaceuticals pays out 28.3% of its earnings in the form of a dividend. As a group, “Healthcare Providers & Services” companies pay a dividend yield of 1.5% and pay out 25.5% of their earnings in the form of a dividend.

Earnings & Valuation

This table compares Shanghai Pharmaceuticals and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Shanghai Pharmaceuticals	N/A	N/A	1.51
Shanghai Pharmaceuticals Competitors	$20.56 billion	$279.23 million	0.97

Shanghai Pharmaceuticals’ rivals have higher revenue and earnings than Shanghai Pharmaceuticals. Shanghai Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Institutional & Insider Ownership

6.8% of Shanghai Pharmaceuticals shares are held by institutional investors. Comparatively, 57.7% of shares of all “Healthcare Providers & Services” companies are held by institutional investors. 15.3% of shares of all “Healthcare Providers & Services” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Shanghai Pharmaceuticals beats its rivals on 5 of the 9 factors compared.

Shanghai Pharmaceuticals Company Profile

Shanghai Pharmaceuticals Holding Co., Ltd. engages research, development, manufacture, distribution, and retailing of pharmaceutical and healthcare products in China and internationally. The company operates through four segments: Production, Distribution, Retail, and Others. It offers chemicals and biochemicals, Chinese medicines, healthcare products, and medical devices in various therapeutic areas, including digestive system, immune metabolism, motor neuron disease, endocrinology, cardiovascular, psychoneurotic, neoplasm, autoimmunity, systemic anti-infection, mental nerve, anti-tumor, oncology, respiratory system, nervous system, auto-immunity, hypertension, neuromyelitis, diabetes, anticholinesterase, polypeptide hormones uterine tonic, antihistamine, anti-inflammatory, anesthetic, immunomodulatory, antiviral, reflux esophagitis, analgesics, weight management, malignant peritoneal effusion, ulcerative colitis, myasthenia gravis, burn injury, anticoagulant, anti-epileptic, anticonvulsant, Alzheimer’s, and inflammatory bowel diseases. The company also engages in the provision of pharmaceutical distribution, warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, it engages in the operation of a network of retail pharmacy stores. The company was incorporated in 1994 and is headquartered in Shanghai, China.